Dr John Houston named one of The Top 25 Biotech CEOs of 2021.

Published: 21 April 2021

John Houston is the President and Chief Executive Officer of Arvinas, a biopharmaceuticals company focused on oncology treatment.

University of Glasgow alumnus, Dr John Houston, has been named one of the Top 25 Biotech CEOs of 2021. Dr Houston graduated with a BSc in Medical Microbiology (1981) and returned to Glasgow for his post-doc with Professor Julia Douglas (1985-88), after receiving his PhD (1985) in Microbial Biochemistry from Heriot-Watt University, Edinburgh.

The past twelve months, more than any other period in recent history, have showcased the outstanding talent, ingenuity, and determination of the world’s leading biotechnology executives and their organisations. From hundreds of nominees, Dr Houston and the other CEOs were selected for their continued dedication to patient care, and their significant contributions to the advancement of medicine.

Dr Houston is President and Chief Executive Officer of Arvinas. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

Dr Houston's success at Arvinas is not surprising considering his nearly 30 years of experience in the ranks of two major biopharma R&D organizations. With his teams and research colleagues, he progressed over 200 compounds into early development, several of which advanced into late-stage clinical trials, and toward commercialization.

In addition to his many roles at Arvinas, Dr Houston also currently serves on the boards of directors of Oerth Bio, Cybrexa Therapeutics, and BioCT.

The University is always delighted to see our world-changing alumni recognised for their achievements, and is pleased to congratulate Dr Houston on his nomination.

First published: 21 April 2021